Pancreatic Adverse Events Associated With Immune Checkpoint Inhibitors: A Large-Scale Pharmacovigilance Analysis

Backgrounds: Immune checkpoint inhibitors (ICIs) are considered cornerstones of oncology treatment with durable anti-tumor efficacy, but the increasing use of ICIs is associated with the risk of developing immune-related adverse events (irAEs). Although ICI-associated pancreatic adverse events (AEs)...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yue, Fang, Yisheng, Wu, Jianhua, Huang, Genjie, Bin, Jianping, Liao, Yulin, Shi, Min, Liao, Wangjun, Huang, Na
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9012537/
https://www.ncbi.nlm.nih.gov/pubmed/35431928
http://dx.doi.org/10.3389/fphar.2022.817662

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9012537/
https://www.ncbi.nlm.nih.gov/pubmed/35431928
http://dx.doi.org/10.3389/fphar.2022.817662

Ejemplares similares